A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy Subjects
Completed
The purpose of this study is to determine the safety, tolerability, pharmacokinetics and
pharmacodynamics of ALN-TTRSC02 in healthy subjects.
Trial at a Glance
- Trial ID
- ALN-TTRSC02-001
- Condition
- Transthyretin Amyloidosis (ATTR)
- Drug/Treatment
- Vutrisiran
- Does this trial use a placebo?
- Yes
- Trial Type
- Interventional
- Number of Participants
- 80 participants
- Trial dates
- June 7, 2016 - January 12, 2018
For more information:NCT02797847
Who participated?
AGE
18 to 65 Years
SEX
All
ACCEPTS HEALTHY VOLUNTEERS?
Yes
Inquire about a clinical trial
Contact Alnylam directly with any questions about our clinical trials.
Inquire about a clinical trial
Contact Alnylam directly with any questions
about our clinical trials.
about our clinical trials.
